Interleukin-33 promotes the proliferation of mouse mast cells through St2/MyD88 and p38 MAPK-dependent and Kit-independent pathways

Journal of Biological Regulators and Homeostatic Agents

Volumn 28, Issue 4, 2014, Pages 575-585

  Saluja, R ^a   Hawro, T ^a   Eberle, J ^a   Church, M K ^a   Maurer, M ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Apoptosis; ERK; IL 33; JNK; Kit; Mast cell; P38 MAPK; Proliferation; ST2

Indexed keywords

INTERLEUKIN 1 RECEPTOR LIKE 1 PROTEIN; INTERLEUKIN 33; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE P38; MYELOID DIFFERENTIATION FACTOR 88; STEM CELL FACTOR; IL1RL1 PROTEIN, MOUSE; INTERLEUKIN DERIVATIVE; INTERLEUKIN RECEPTOR; INTERLEUKIN-33, MOUSE; MYD88 PROTEIN, MOUSE; STEM CELL FACTOR RECEPTOR;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL ACTIVATION; CELL CYCLE; CELL CYCLE ASSAY; CELL CYCLE G2 PHASE; CELL PROLIFERATION; CELL VIABILITY; CYTOKINE PRODUCTION; CYTOTOXICITY; IN VITRO STUDY; IN VIVO STUDY; MAST CELL; MAST CELL DEGRANULATION; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; SIGNAL TRANSDUCTION; SKIN; WST ASSAY; ANIMAL; C57BL MOUSE; DEGRANULATION; DRUG EFFECTS; PHYSIOLOGY;

ANIMALS; CELL DEGRANULATION; CELL PROLIFERATION; INTERLEUKINS; MAST CELLS; MICE; MICE, INBRED C57BL; MYELOID DIFFERENTIATION FACTOR 88; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTO-ONCOGENE PROTEINS C-KIT; RECEPTORS, INTERLEUKIN;

EID: 84925297818     PISSN: 0393974X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Shelburne CP, Abraham SN. The mast cell in innate and adaptive immunity. Adv Exp Med Biol 2011;716:162-85.
2. Brown JM, Wilson TM, Metcalfe DD. The mast cell and allergic diseases: role in pathogenesis and implications for therapy. Clin Exp Allergy 2008;38(1):4-18.
3. Fodinger M, Fritsch G, Winkler K, Emminger W. Mitterbauer G, Gadner H, Valent P, Mannhalter C. Origin of human mast cells: development from transplanted hematopoietic stem cells after allogeneic bone marrow transplantation. Blood 1994;84(9):2954-59.
4. Nabe T, Matsuya K, Akamizu K, et al. Roles of basophils and mast cells infiltrating the lung by multiple antigen challenges in asthmatic responses of mice. Br J Pharmacol 2013;169(2):462-76.
5. Hershko AY, Charles N, Olivera A, Alvarez-Errico D, Rivera J. Cutting edge: persistence of increased mast cell numbers in tissues links dermatitis to enhanced airway disease in a mouse model of atopy. J Immunol 2012;188(2):531-35.
6. Mathias CB, Freyschmidt EJ, Caplan B, et al. IgE influences the number and function of mature mast cells, but not progenitor recruitment in allergic pulmonary inflammation. J Immunol 2009;182(4):2416-24.
7. Kassel O, de Blay F, Duvernelle C, et al. Local increase in the number of mast cells and expression of nerve growth factor in the bronchus of asthmatic patients after repeated inhalation of allergen at lowdose. Clin Exp Allergy 2001;31(9):1432-40.
8. Da Silva CA, Reber L, Frossard N. Stem cell factor expression, mast cells and inflammation in asthma. Fundam Clin Pharmacol 2006;20(1):21-39.
9. Schmitz J, Owyang A, Oldham E, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 2005;23(5) 479-90.
10. Moritz DR, Rodewald HR, Gheyselinck J, Klemenz R. The IL-1 receptor-related T1 antigen is expressed on immature and mature mast cells and on fetal blood mast cell progenitors. J Immunol 1998;161(9) 4866-74.
11. Hsu CL, Neilsen CV, Bryce PJ. IL-3 3 is produced by mast cells and regulates IgE-dependent inflammation. PLoS One 2010;5(8):e11944.
12. Sabatino G, Nicoletti M, Neri G, et al. Impact of IL-9 and IL-33 in mast cells. J Biol Regul Homeost Agents 2012;26(4):577-86.
13. Ohno T, Morita H, Arae K, Matsumoto K, Nakae S. Interleukin-33 in allergy. Allergy 2012;67(10):1203-14.
14. Nakae S, Morita H, Ohno T, Arae K, Matsumoto K, Saito H. Role of interleukin-33 in innate-type immune cells in allergy. Allergol Int 2013;62(1):13-20.
15. Mrabet-Dahbi S, Metz M, Dudeck A, Zuberbier T, Maurer M. Murine mast cells secrete a unique profile of cytokines and prostaglandins in response to distinct TLR2 ligands. Exp Dermatol 2009;18(5):437-44.
16. Gomez G, Ramirez CD, Rivera J, et al. TGF-beta 1 inhibits mast cell Fc epsilon RI expression. J Immunol 2005;174(10):5987-93.
17. Berger A, Quast SA, Plotz M, Hein M, Kunz M. Langer P, Eberle J. Sensitization of melanoma cells for death ligand-induced apoptosis by an indirubin derivative-Enhancement of both extrinsic and intrinsic apoptosis pathways. Biochem Pharmacol 2011;81(1):71-81.
18. Saluja R, Delin I, Nilsson GP, Adner M. FcepsilonRlmediated mast cell reactivity is amplified through prolonged Toll-like receptor-ligand treatment. PLoS One 2012;7(8):e43547.
19. Drube S, Heink S, Walter S, et al. The receptortyrosine kinase c-Kit controls IL-33 receptor signaling in mast cells. Blood 2010;115(19):3899-906.
20. Hueber AJ, Alves-Filho JC, Asquith DL, et al. IL-33 induces skin inflammation with mast cell and neutrophil activation. Eur J Immunol 2011;41(8) 2229-37.
21. Enoksson M, Moller-Westerberg C, Wicher G, Fallon PG, Forsberg-Nilsson K, Lunderius-Andersson C, Nilsson G. Intraperitoneal influx of neutrophils in response to IL-33 is mast cell-dependent. Blood 2013;121(3):530-36.
22. Savinko T, Matikainen S, Saarialho-Kere U, et al. IL-33 and ST2 in atopic dermatitis: expression profiles and modulation by triggering factors. J Invest Dermatol 2012;132(5):1392-400.
23. Wang JX, Kaieda S, Ameri S, et al. IL-33/ST2 axis promotes mast cell survival via BCLXL. Proc Natl Acad Sci USA 2014;111(28):10281-86.
24. Kakkar R, Lee RT. The IL-33/ST2 pathway: therapeutic target and novel biomarker. Nat Rev Drug Discov 2008;7(10):827-40.
25. Enoksson M, Lyberg K, Moller-Westerberg C, Fallon PG, Nilsson G, Lunderius-Andersson C. Mast cells as sensors of cell injury through IL-33 recognition. J Immunol 2011;186(4) 2523-8.
26. Ho LH, Ohno T, Oboki K, et al. IL-33 induces IL-13 production by mouse mast cells independently of IgE-FcepsilonRI signals. J Leukoc Biol 2007;82(6):1481-90.
27. Tung HY, Plunkett B, Huang SK, Zhou Y. Murine mast cells secrete and respond to interleukin-33. J Interferon Cytokine Res 2014;34(3):141-7.
28. Yang DX, Li N, Zhang XL, Wang Q. [Serum interleukin 18 and 33 levels and its clinical significance in asthma patients]. Zhonghua Jie He He Hu Xi Za Zhi 2012;35(7):493-6.
29. Hamzaoui A, Berraies A, Kaabachi W, Haifa M, Ammar J, Kamel H. Induced sputum levels of IL-33 and soluble ST2 in young asthmatic children. J Asthma 2013;50(8):803-9.
30. Bentley AM, Jacobson MR, Cumberworth V, et al. Immunohistology of the nasal mucosa in seasonal allergic rhinitis: increases in activated eosinophils and epithelial mast cells. J Allergy Clin Immunol 1992;89(4):877-83.
31. Iikura M, Suto H, Kajiwara N, et al. IL-33 can promote survival, adhesion and cytokine production in human mast cells. Lab Invest 2007;87(10):971-8.
32. Andrade MV, Iwaki S, Ropert C, Gazzinelli RT, Cunha-Melo JR, Beaven MA. Amplification of cytokine production through synergistic activation of NFAT and AP-1 following stimulation of mast cells with antigen and IL-33. Eur J Immunol 2011;41(3):760-72.
33. Allakhverdi Z, Smith DE, Comeau MR, Delespesse G. Cutting edge: The ST2 ligand IL-33 potently activates and drives maturation of human mast cells. J Immunol 2007;179(4) 2051-4.